Home | Medical-Newswire.Com:
(Medical-NewsWire.com, May 20, 2022 ) The global molecular diagnostics market is valued at an estimated USD 23.2 billion in 2022 and is projected to reach USD 30.2 billion by 2027, at a CAGR of 5.4%.
Major Growth Boosting Factors:
The molecular diagnostics market is driven by the growing awareness of early disease diagnosis in developing countries and the rising technological advancements in molecular diagnostics. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the molecular diagnostics market.
The infectious disease diagnostics segment accounted for the largest share of the molecular diagnostics market, by application segment, in 2021
Based on applications, the molecular diagnostics market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The infectious disease diagnostics segment accounted for the largest share of the global molecular diagnostics market in 2021. Factors such as the increasing prevalence of infectious diseases and the outbreak of COVID-19 are boosting the market growth of this segment.
Download PDF Brochure@
Diagnostic laboratories segment to register the highest growth rate during the forecast period
The molecular diagnostics market has been segmented into diagnostic laboratories, hospitals & clinics, and other end users. In 2021, diagnostic laboratories accounted for the highest growth rate. The development of complex and highly specialized tests in molecular diagnostics and oncology is expected to drive the growth of the molecular diagnostics market for diagnostic laboratories.
North America is the largest regional market for molecular diagnostics market
The global molecular diagnostics market has been segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the molecular diagnostics market. The large share of this region can be attributed to the growing geriatric population, the implementation of favorable government initiatives, increasing healthcare expenditures, improved healthcare infrastructures, the availability of technologically advanced molecular diagnostic instruments, the highly developed healthcare system in the US and Canada, and the high burden of infections and cancers.
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), bioMérieux SA (France), QIAGEN N.V. (Netherlands), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), and Danaher Corporation (US).
Request Sample Pages@
Mr. Aashish Mehra